Overview
Ori Biotech offers the IRO platform, a proprietary system that automates, standardizes, and scales cell and gene therapy (CGT) manufacturing, particularly for cell therapies like CAR-T. The compact, flexible platform reduces costs, processing times, and labor while improving quality through integrated hardware, software, and data services. It supports end-to-end workflows from preclinical development to commercial scale and integrates with partner technologies for closed, efficient processing.
Frequently asked questions
- What capabilities does Ori Biotech's IRO platform provide for CGT manufacturing?
- The IRO platform automates and standardizes cell therapy manufacturing, including novel bioreactors, cloud-native digital data capture every seven seconds, and flexible scalability via stackable microwave-sized devices, supporting CAR-T and other processes from preclinical to commercial scale.
- What regulatory and quality features does the IRO platform offer?
- The platform enables closed, automated workflows that improve quality, reduce contamination risks, and standardize processes, with demonstrated integration into validated systems like Fresenius Kabi's Cue and Lovo for efficient upstream and downstream processing.
- In which geographies does Ori Biotech operate and support manufacturing?
- Ori Biotech is based in London (UK), New Jersey, and Philadelphia (US), with data from internal and partner sites worldwide, enabling global access to scalable CGT manufacturing.